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Introduction
Preimplantation genetic diagnosis (PGD) is an alternative 
to  prenatal  diagnosis  involving  the  biopsy  and  genetic 
testing of single cells from in vitro obtained oocytes and/
or preimplantation embryos. Only embryos shown to be 
free of the genetic defect under study are transferred to 
the uterus of the patient. PGD is performed for couples at 
high  risk  of  transmitting  a  genetic  condition  to  their 
children;  it  offers  the  advantage  of  circumventing  an 
invasive prenatal diagnosis and therapeutic abortion.
Preimplantation genetic screening (PGS) involves the 
selection of euploid embryos to improve in vitro fertili  za­
tion (IVF) results and to avoid pregnancies with chromo­
somal abnormalities [1]. Considering the increasing risk 
for aneuploidy with advanced maternal age and findings 
of high aneuploidy rates in spontaneous abortions, PGS 
has been offered to specific IVF patient groups: patients 
of  advanced  maternal  age  and  patients  with  recurrent 
IVF failure or repeated miscarriages (not due to trans­
locations). For many years, PGS using fluorescence in situ 
hybridization (FISH) for 5 to 12 chromosomes has been 
applied  worldwide  but  without  real  validation  of  its 
efficiency. In recent years, several randomized controlled 
trials have failed to show a benefit for PGS, as summar­
ized in the meta­analysis by Checa and colleagues [2]. 
Biological (embryonic mosaicism) and technical (limita­
tions  of  FISH  and  negative  impact  of  cleavage­stage 
biopsy) arguments were proposed to explain the lack of 
benefit.  Further  clinical  practice  now  awaits  new 
random  ized  controlled  trials  to  prove  that  PGS  with 
biopsy at other stages, and using new array methods with 
full chromosome analysis, improves live birth rates and 
reduces miscarriage rates [3]. PGD and PGS rely on the 
same technology, but since PGS is offered to (sub)fertile 
couples without genetic diseases, it is mostly outside the 
scope of this review.
PGD developed in the wake of human IVF and PCR 
technology.  The  first  children  born  after  PGD  were 
reported by Handyside et al. in 1990 [4]. In these initial 
cycles,  PCR  was  used  for  gender  determination  in 
families with X­linked diseases. Later, FISH became the 
standard method for sexing, and also for chromosomal 
aberrations, while PCR­based methods were used for the 
detection of single gene defects. It is essential that these 
techniques  are  adapted  to  the  single­cell  level  and  are 
thoroughly validated before clinical application.
PGD  requires  a  multidisciplinary  team  with  a  close 
collaboration and excellent communication between the 
assisted reproduction unit and the medical genetics unit. 
Preferentially, both units work within the same institute. 
Alternatively,  transport  PGD  can  be  set  up,  and  IVF 
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vitro fertilization, embryo culture and embryo transfer) is 
carried out at a satellite assisted­reproduction unit. Only 
the  biopsied  embryonic  cell  samples  are  transported, 
often over long distances, to a genetics unit specializing 
in single­cell diagnosis.
Extensive data on PGD cycles, pregnancies, deliveries 
and children have been collected by the European Society 
for Human Reproduction and Embryology (ESHRE) PGD 
consortium since 1997 and, although not worldwide, the 
data sets offer comprehensive insights into this particular 
field of single­cell testing [5].
Indications for preimplantation genetic diagnosis
The main indications for PGD are chromosomal abnor­
mali  ties,  X­linked  disorders  and  single  gene  or  mono­
genic  disorders.  The  majority  of  PGD  cycles  for 
chromosomal abnormalities are aimed at reciprocal and 
Robertsonian translocations, while cases with inversions 
or insertions are less frequent. For the monogenic dis­
orders, PGD was initially applied for the same indica  tions 
as in prenatal diagnosis. According to the latest ESHRE 
PGD consortium data, the most common indications for 
autosomal recessive disorders are cystic fibrosis, spinal 
muscular atrophy and hemoglobinopathies [6]. For the 
autosomal dominant disorders, myotonic dystrophy type 
1,  neurofibromatosis  and  Huntington’s  disease  are  the 
most frequently requested indications; for the X­linked 
disorders,  PGD  is  mainly  carried  out  for  Duchenne’s 
muscular dystrophy, hemophilia and fragile X syndrome. 
Sexing with FISH has been most frequently used for X­
linked  disorders  but  more  and  more  specific  DNA 
diagnoses have been developed. Specific DNA diagnosis 
has  important  advantages:  first,  healthy  male  embryos 
are  not  discarded;  and  second,  female  carriers  can  be 
identified and excluded from transfer or not, according to 
the wishes of the patient and the policy of the center.
PGD is currently available for more than 200 mono­
genic diseases and has lately also been applied for indica­
tions, such as cancer predisposition syndromes and other 
late­onset  diseases,  for  which  prenatal  diagnosis  is 
ethically  difficult  [7,8].  For  cancer  predisposition  syn­
dromes that are not fully penetrant and for which some 
form of therapeutic measures may be available, prenatal 
diagnosis and termination of pregnancy remain contro­
versial.  As  the  preimplantation  embryo  is  often  con­
sidered  as  having  less  moral  value  than  a  fetus,  PGD 
seems a more acceptable option.
Another  more  recent  indication  is  human  leucocyte 
antigen  (HLA)  typing  of  preimplantation  embryos  to 
select an embryo that is HLA compatible with an affected 
sibling. At birth, hematopoietic stem cells from the cord 
blood of the saviour baby are then used to transplant the 
sick sibling. HLA typing alone is carried out for acquired 
diseases, such as severe aplastic anemia, or HLA typing is 
combined  with  the  detection  of  mutations  underlying 
immunodeficiencies  and  hemoglobin  disorders  [9­  11]. 
The major ethical objection here is that the future child 
may be regarded as an instrument and not as an autono­
mous person. This concern was studied in depth and it 
was concluded that considering the efforts of the parents 
to cure the sick child and their wish for another child, it is 
unlikely that they would treat the saviour child solely as a 
donor. In addition, it is universally accepted to rely on an 
existing  HLA­compatible  child  as  a  donor  of  hemato­
poietic stem cells [12].
So  far,  few  clinical  cycles  have  been  carried  out  for 
families carrying heteroplasmic mitochondrial (mt)DNA 
mutations [13­15]. The genetics of mtDNA is quite com­
plex and the proportion of mutant mtDNA trans  mitted 
from  mother  to  offspring  will  vary  due  to  a  genetic 
bottleneck  in  the  oocytes  [16].  It  is  another  ethically 
difficult indication, as the possibility exists that there are 
no zero­mutation embryos for transfer but just embryos 
with a low mutation load (that is, the ratio of mutant to 
normal  mtDNA)  under  a  certain  disease­specific 
threshold, meaning that the risk for an affected child is 
not  eliminated  but  only  reduced.  PGD  for  mtDNA 
mutations  can  only  be  offered  reliably  when  certain 
criteria  are  fulfilled:  a  close  correlation  between  the 
mutation load and disease severity is a first requirement; 
second, there should be no change in mutation load with 
time;  and  third,  mutant  mtDNA  should  be  uniformly 
distributed  over  all  blastomeres  of  the  cleavage­stage 
embryo  [17].  For  many  mtDNA  mutations  the  latter 
information is not available. Therefore, it is recommended 
to develop PGD within a scientific research protocol and 
to  counsel  prospective  parents  adequately  and  inform 
them that a first PGD cycle may be carried out merely to 
gather information on the reliability of PGD [18].
Assisted reproductive technology and biopsy
The first step in a PGD cycle is controlled ovarian hyper­
stimulation, aimed at obtaining a large cohort of mature 
oocytes. The aspirated oocytes are denuded of surround­
ing  cumulus  cells  before  IVF  occurs.  Intracytoplasmic 
sperm injection is preferred over regular IVF, regardless 
of  the  sperm  quality,  in  order  to  avoid  residual  sperm 
adhering  to  the  zona  pellucida  after  IVF.  Remaining 
cumulus or sperm cells may lead to contamination when 
PCR is used for diagnosis [19].
The biopsy procedure involving breaching of the zona 
pellucida and removal of the cell(s) can be carried out at 
different  developmental  stages  [20].  Polar  body  (PB) 
biopsy from oocytes (first PB from metaphase II oocytes 
and  second  PB  after  normal  fertilization)  is  a  first 
possibility  [21].  As  PBs  do  not  contribute  to  normal 
fertilization  or  embryonic  development,  their  removal 
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selection is forbidden, PB biopsy is the only legal option 
as testing can take place before syngamy, which is the 
moment considered as the beginning of an embryo. The 
main disadvantage is that PB analysis can only evaluate 
the  maternal  genetic  contribution.  The  ESHRE  PGD 
consortium data collection indicates that cleavage­stage 
biopsy at day 3 is used in the majority of PGD cycles [6]. 
At  this  eight­cell  stage,  embryo  compaction  has  not 
started yet and cells are considered to be totipotent. The 
zona pellucida opening is mostly carried out with a non­
contact  diode  infrared  laser  and  one  or  two  nucleated 
blastomeres are aspirated [22]. The impact of the random 
removal  of  one  or  two  embryonic  cells  on  further 
development  and  implantation  potential  is  highly 
debated. In a recent prospective analysis of a cohort of 
single­embryo transfers, the authors demonstrated that 
the live birth rate after one­cell removal from eight­cell 
embryos  (37.4%)  is  similar  to  the  rate  of  a  control 
intracytoplasmic sperm injection group without biopsy 
(35.0%), but significantly higher than the rate of the two­
cell  biopsy  study  group  (22%).  It  is  therefore  recom­
mended to biopsy one cell, provided that an accurate and 
reliable diagnosis method is in place [23]. Another limita­
tion  of  cleavage­stage  biopsy  is  the  high  chromosomal 
mosaicism rate that seems inherent at this developmental 
stage and probably evolves to lower rates at the blastocyst 
stage via self­correction [24]. Trophectoderm (TE) biopsy 
at day 5 is a fast emerging biopsy approach. Some reports 
suggest that it may yield substantially higher implantation 
and live birth rates than cleavage­stage biopsy [25­27]. 
About 4 to 20 extra­embryonic TE cells are aspirated and 
the inner cell mass, from which the fetus will develop, is 
kept  intact.  This  is  one  advantage  compared  with 
cleavage­stage biopsy; another advantage is that multiple 
cells  are  available  for  genetic  testing,  and  this  may 
improve  diagnostic  accuracy.  The  drawbacks  of  TE 
biopsy are that it requires a successful embryo culture 
system  with  high  blastocyst  rates  and  it  leaves  limited 
time  for  genetic  analysis.  The  time  problem  may  be 
solved  by  freezing  the  blastocysts,  relying  on  efficient 
vitrification and thaw­survival protocols, and transferring 
them later in a natural cycle.
After biopsy, (single) cells are washed and either fixated 
for FISH analysis or tubed and lysed for amplification. 
Amplification reaction components are added directly to 
the lysed cells without prior DNA purification.
Single-cell genetic testing for monogenic disorders
In  principle,  any  monogenic  disease  for  which  the 
chromosomal locus has been identified can be diagnosed 
at  the  single­cell  level.  The  golden  standard  today  is 
fluorescent multiplex PCR in which one of each primer 
pair  is  fluorescently  labeled,  allowing  subsequent 
detection of PCR fragments on an automated sequencer. 
In indirect tests, multiple short tandem repeat markers 
are co­amplified together in one reaction (linkage­based 
strategy); for direct testing, markers are combined with 
specific  mutation(s).  The  main  advantage  of  linkage­
based testing over mutation­specific testing is that the 
single­cell  protocols  can  be  used  for  several  couples, 
independent of the mutation they carry. This saves time, 
resources  and  manpower  in  pre­PGD  workups  for 
diseases  for  which  many  private  mutations  have  been 
identified.  The  use  of  polymorphic  markers  implicates 
that during pre­PGD work up, informativity and segre­
gation tests are performed on DNA samples of the couple 
and  family  members  to  establish  which  alleles  of  the 
informative  markers  segregate  with  the  mutation. 
Different strategies of PCR and allele discrimination have 
been developed for mutation detection over recent years, 
and the most important ones are: amplification refractory 
mutation  system  [28],  endonuclease  restriction  [29], 
minisequencing [30] and quantitative real­time PCR [26]. 
PCR­based protocols with short tandem repeat markers 
have  recently  also  been  applied  in  PGD  cycles  for 
structural chromosome abnormalities, in which FISH has 
been traditionally the preferred method [31,32]. A major 
bottleneck with PCR assays is that the single­cell adap­
tation and validation part of the pre­PGD work up has to 
be repeated with every new DNA locus. In recent years, 
the use of single­cell whole genome amplification (WGA) 
as  a  universal  step  has  been  demonstrated  to  be  a 
practical and efficient alternative to single­cell PCR. The 
first WGA methods were PCR­based and suffered from 
incomplete genome coverage and amplification bias, but 
the more recent methods are markedly better [33]. One 
method is multiple displacement amplification that relies 
on  isothermal  strand  displacement  amplification  with 
Phi29  DNA  polymerase.  This  method  is  very  straight­
forward but requires high­quality DNA as the template, 
and  yields  relatively  high  allele  drop­out  (ADO)  and 
preferential amplification rates of 25% on average [34]; 
this  is  about  five  times  higher  than  with  fluorescent 
multiplex PCR. Other WGA methods involve somewhat 
more  complex  protocols  with  DNA  fragmentation  and 
library  formation  prior  to  amplification;  they  even 
amplify low­quality DNA, and ADO rates are approxi­
mately 10% [35]. Single­cell WGA generates micrograms 
of amplified DNA, which is sufficient for several down­
stream applications. Multiple standard PCR assays may 
be  performed  for  haplotyping  in  case  of  monogenic 
diseases  [36].  Haplotyping  can  also  be  combined  with 
array comparative genomic hybridization (aCGH) for the 
detection of chromosomal imbalances. These strategies 
are  already  clinically  applied  in  some  centers.  Further 
improvement and generalization will come from the intro­
duction of high­density single nucleotide polymorphism 
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typing  and  chromosomal  constitution  on  the  same 
platform. The validation of these SNP arrays is ongoing 
[37,38]. The implementation of these new technologies 
will  reduce  the  procedures  substantially  and  introduce 
automation. On the other hand, these arrays will generate 
a tremendous amount of genetic data ­ for instance, on 
disease susceptibility genes ­ and it is expected that this 
will  entail  many  ethical  discussions  and  challenges  for 
genetic counseling.
Single-cell genetic testing for chromosomal 
aberrations
The majority of PGD cycles for chromosomal aberrations 
are performed for translocations. Balanced translocation 
carriers have a high risk for producing chromosomally 
unbalanced  gametes  and  present  with  infertility, 
repeated  spontaneous  abortions  and  unbalanced 
offspring. With FISH, fixated cells are hybridized using 
chromosome­specific  DNA  probes,  which  are  labeled 
with  different  fluorochromes.  Probe  selection  is  based 
on  the  break  points  of  the  specific  translocation  and 
chromosomes involved, and should allow detection of all 
possible  segregation  patterns.  FISH  has  a  number  of 
technical  limitations  and  it  is  gradually  replaced  by 
aCGH. Here, whole genome amplified DNA of the test 
single­cell(s) is labeled with a green fluorochrome, while 
a red fluoro  chrome is used for the control sample. Both 
samples  are  mixed  and  hybridized  to  either  a  normal 
metaphase chromosome spread or, in case of aCGH, to 
DNA  sequences  specific  to  human  chromosomes 
spotted  on  an  array.  A  computerized  system  allows 
analysis  of  the  ratios  between  both  fluorochromes  for 
each  chromosome  and  detection  of  imbalances.  As 
metaphase comparative genomic hybridization (CGH) at 
the  single­cell  level  requires  several  days  for  analysis, 
groups that have presented clinical application of CGH 
in PGD have to resort to either polar body analysis [39] 
or cryo  preservation of the embryos [40,41]. As aCGH 
has  a  lower  hybridization  time,  it  can  be  performed 
within the time frame of PGD. Other advantages over 
metaphase  CGH  are  the  higher  resolution  and  the 
important  auto  mation  [42].  aCGH  following  multiple 
displacement  amplification  has  been  preclinically 
validated  in  single  lymphoblasts,  fibroblasts  and 
blastomeres  of  trans  loca  tion  carriers  [43],  and  clinical 
data  have  been  published  for  PGS  applications  [44]. 
Compared  with  FISH,  aCGH  provides  a  generalized 
platform,  circumventing  pre­PGD  testing  of  FISH 
probes with every new translocation. aCGH, as well as 
SNP  arrays,  yields  information  on  genome­wide  copy 
number  variation,  but  only  SNP  arrays  offer 
simultaneously  genotype  information  and  present  a 
universal  platform  for  both  chromosomal  aberrations 
and  monogenic  diseases.  Therefore,  SNP  arrays  are 
regarded as the most promising future strategy for PGD.
Accuracy
Single­cell DNA amplification is technically demanding 
because of the small amount of non­purified DNA at the 
start, and inherent pitfalls of contamination and ADO, 
which can lead to misdiagnosis. ADO is defined as the 
random failure of amplification for one of two alleles in a 
heterozygous  cell.  The  use  of  optimized  cell  lysis  and 
DNA  amplification  conditions,  along  with  sensitive 
detection systems, should reduce ADO to a minimum. 
Contamination  is  minimized  by  taking  a  number  of 
prevention measures (see best practice guidelines). The 
application of multiplex PCR protocols further assists in 
monitoring  problems  of  contamination  and  ADO  in 
addition  to  mutation  detection,  making  these  assays 
highly accurate.
A  recent  theoretical  study  on  the  accuracy  of  FISH 
showed  that  the  technology  has  the  potential  of  high 
accuracy for sexing and for translocations, but not in the 
case of aneuploidy screening [45]. Apart from technical 
errors such as ADO and contamination, other possible 
causes for misdiagnosis involve intrinsic sample quality, 
such  as  chromosomal  mosaicism,  and  human  errors, 
such  as  mislabeling,  incorrect  embryo  transfer  or 
erroneous  segregation  analysis.  According  to  the  PGD 
consortium data, low error rates have been observed for 
both DNA­amplification­based cycles (0.5%) and FISH­
based cycles (0.1%) [46].
Quality control and assurance
PGD is still relatively unregulated compared with routine 
genetic testing. In order to better standardize single­cell 
testing and to achieve high quality levels, guidelines for 
best  practice  have  been  designed  by  the  ESHRE  PGD 
consortium and by the Preimplantation Genetic Diag  nosis 
International  Society  [47­49].  In  addition,  four  new 
extensive guidelines on different aspects of PGD (organi­
za  tion of a PGD center, FISH­based testing, amplification­
based testing and biopsy) are in preparation.
A powerful method for quality assurance is accredita­
tion. In 2008, only 33% of 53 European PGD centers had 
achieved or were preparing for accreditation [50]. Many 
countries and international authorities now recommend 
PGD centers to initiate the accreditation process; that is, 
to be committed not only to reach the standards set by 
the  accrediting  body  but  also  to  continuously  enhance 
the quality of the services.
Two programs of external quality assessment (EQA), a 
key  element  of  quality  assurance  [51,52],  have  been 
initiated  recently.  The  UK  National  External  Quality 
Assess  ment  Service  [53],  in  collaboration  with  the 
ESHRE PGD consortium, has set up EQA programs for 
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EQA  program  is  run  by  the  Cytogenetics  European 
Quality Assessment [54].
Conclusions
In  the  past  two  decades,  PGD  has  evolved  from  an 
experimental procedure to a widely accepted alternative 
for  prenatal  diagnosis  that  is  applied  to  an  expanding 
range of indications. Non­stop technical improvements 
have provided reliable and accurate single­cell assays for 
both  chromosomal  abnormalities  and  monogenic  dis­
orders.  As  protocols  are  often  family  specific,  their 
develop  ment is labour intensive and time consuming and 
can  be  carried  out  in  specialized  laboratories.  The 
introduction  of  powerful  array  technologies  following 
universal  whole  genome  amplification  will  reduce  the 
workload  and  allow  automation.  Together  with  the 
imple  mentation of accreditation schemes, this will lead 
to  improved  standardization  and  uniformity  in  the 
complex process of PGD.
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